ストックスクリーナーアプリを入手
4.49
16.07%
-0.86
前日終値:
$5.35
開ける：
$4.37
24時間の取引高:
636.39K
Relative Volume:
3.42
時価総額：
$1.59B
収益：
$842.96M
当期純損益:
$-185.63M
株価収益率:
-13.15
EPS:
-0.3415
ネットキャッシュフロー:
$-228.52M
1週間 パフォーマンス:
-17.46%
1か月 パフォーマンス:
+37.31%
6か月 パフォーマンス:
-13.15%
1年 パフォーマンス:
-56.53%
1日の値動き範囲:
$4.2814
$4.50
1週間の範囲:
$4.2814
$5.63
52週間の値動き範囲:
$2.85
$12.00
Evotec Se Adr Stock (EVO) Company Profile
EVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| EVO | 4.49 | 1.59B | 842.96M | -185.63M | -228.52M | -0.3415 |
| ZTS | 176.96 | 79.73B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.65 | 43.70B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.38 | 42.47B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.12 | 19.40B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.37 | 15.88B | 15.05B | -883.30M | 1.89B | 1.53 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-08 | アップグレード | Citigroup | Neutral → Buy |
| 2023-04-04 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-16 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-08-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2022-01-07 | 再開されました | Citigroup | Neutral |
すべてを表示
Evotec Se Adr (EVO) 最新ニュース
Evotec SE withdraws acquisition offer - Investing.com
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal - Benzinga
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Antibody Discovery Market Size Expected to Surge to USD 4.8 - GlobeNewswire Inc.
Evotec stock holds Buy rating with price target from TD Cowen By Investing.com - Investing.com India
Evotec (OTCMKTS:EVTCY) Sets New 52-Week Low at $4.65 - Defense World
Financial Metrics Check: Evotec SE ADR (EVO)'s Ratios for Trailing Twelve Months – DWinneX - The Dwinnex
Healthcare Sector - Morningstar
Ratio Examination: Evotec SE ADR (EVO)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges By Investing.com - Investing.com
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com Canada
Evotec gains R&D license from Centogene for Gaucher disease - Investing.com India
Closing Bell Recap: Evotec SE ADR (EVO) Ends at 5.23, Reflecting a -31.63 Downturn – DWinneX - The Dwinnex
QT to end this December with hardly a whimper: Barclays By Investing.com - Investing.com
Dow Dips Over 100 Points; Ribbon Communications Shares Spike Higher By Benzinga - Investing.com UK
Evotec and Variant Bio partner to develop fibrosis treatments By Investing.com - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Germany stocks mixed at close of trade; DAX down 0.03% By Investing.com - Investing.com
Germany stocks mixed at close of trade; DAX down 0.30% By Investing.com - Investing.com
Evotec: R&D, Customer Growth Not Enough To Offset Headwinds - Seeking Alpha
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus - The Globe and Mail
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Evotec SEADR Shares Near 52-Week LowMarket Mover - Nasdaq
A Peek Into The Markets: US Stock Futures Rise; J&J Secures Emergency Authorization for Covid-19 Vaccine - Benzinga
Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare ConferenceSlideshow (NASDAQ:EVO) - Seeking Alpha
Together for Medicines That MatterEvotec Website (English) - Evotec
Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA
Evotec Se Adr (EVO) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
0.30%
大文字化:
|
ボリューム (24 時間):